Studybox Research CLIA Waiver Studies

Trichomonas vaginalis Point-of-Care Test

Accuracy in the hands of untrained intended-use operators at waived sites.

Studybox

CLIA Waiver Studies

Trichomoniasis is the most common non-viral sexually transmitted infection, and because wet mount microscopy misses a large share of infections, point-of-care antigen and molecular tests have a clear clinical rationale. The clinical study is straightforward in structure, a vaginal swab tested on the device with a paired swab sent to a laboratory NAAT reference, but the reference has shifted: studies that once used wet mount and culture now use NAAT and must explain how culture, if included, contributes to the reference.

Prevalence varies widely by population, from a few percent in general clinics to much higher in some sexual health and emergency department populations, and this variation drives site selection. A male urine claim adds a specimen type and population with lower parasite load and distinct enrollment challenges.

Analyte: Trichomonas vaginalis antigen (lateral flow) or nucleic acid (point-of-care molecular), depending on the device
Therapeutic area: STD/STI Detection
Specimens: Vaginal Swab, Urine
Intended-use settings: urgent care, physician office, emergency department
Operators: Non-laboratory clinic staff in waived settings; laboratory staff for moderate-complexity claims.
Comparator: Typically an FDA-cleared T. vaginalis nucleic acid amplification test, sometimes combined with culture; wet mount microscopy is the historical point-of-care comparator and is no longer an adequate reference because of its low sensitivity.

CLIA Waiver Studies specifics

What Changes for This Assay on This Pathway.

For lateral flow devices, flex studies stress swab expression into buffer, drop count, read time and faint-line interpretation; for cartridge molecular devices, sample transfer and instrument environment.
Waived sites with meaningful prevalence are typically urgent care and family planning clinics in higher-prevalence areas; general practices will produce few positives.
Clinician-collected swabs taken during a pelvic exam are the norm in many settings; if self-collected swabs are claimed, the waiver study must include them.

Endpoints the study must support

Sensitivity and specificity against the NAAT-based reference, with 95% confidence intervals, in women by vaginal swab and, where claimed, in men by urine
Performance in symptomatic and asymptomatic subjects separately
Invalid rate and inter-operator agreement for visually read devices

Enrollment realities

Driven by NAAT-positive women, with prevalence varying several-fold by site type; symptomatic and asymptomatic strata are typically both required and the asymptomatic positives accrue slowly.

How Studybox runs it

Pre-Qualified Sites, Embedded Coordinators.

Waiver evidence depends on genuine intended-use operators in genuine waived settings. Our network of 100+ pre-qualified urgent care, physician office, and point-of-care sites already runs IVD protocols, so operator recruitment and site activation don't start from zero. How we run clia waiver studies →

Same assay, other pathways

Relevant FDA guidance

FAQ

Trichomonas vaginalis Point-of-Care Test Study Questions.

01 Who operates the trichomonas vaginalis point-of-care test in a clia waiver studies study?

Non-laboratory clinic staff in waived settings; laboratory staff for moderate-complexity claims.

02 What is the comparator for a trichomonas vaginalis point-of-care test study?

Typically an FDA-cleared T. vaginalis nucleic acid amplification test, sometimes combined with culture; wet mount microscopy is the historical point-of-care comparator and is no longer an adequate reference because of its low sensitivity.

03 What drives enrollment for a trichomonas vaginalis point-of-care test study?

Driven by NAAT-positive women, with prevalence varying several-fold by site type; symptomatic and asymptomatic strata are typically both required and the asymptomatic positives accrue slowly.

Let's talk IVD research

Planning a trichomonas vaginalis point-of-care test study?

Tell us the intended use and setting. We'll come back with a site plan, operator strategy, and a realistic activation timeline for the clia waiver studies pathway.